Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Research & Development (2018 - 2025)

10x Genomics' Research & Development history spans 8 years, with the latest figure at $56.0 million for Q4 2025.

  • For Q4 2025, Research & Development fell 16.42% year-over-year to $56.0 million; the TTM value through Dec 2025 reached $238.6 million, down 9.85%, while the annual FY2025 figure was $238.6 million, 9.85% down from the prior year.
  • Research & Development for Q4 2025 was $56.0 million at 10x Genomics, down from $57.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $71.5 million in Q2 2023 and bottomed at $41.9 million in Q1 2021.
  • The 5-year median for Research & Development is $64.2 million (2022), against an average of $62.6 million.
  • The largest annual shift saw Research & Development skyrocketed 93.94% in 2021 before it dropped 16.42% in 2025.
  • A 5-year view of Research & Development shows it stood at $61.9 million in 2021, then increased by 2.79% to $63.6 million in 2022, then grew by 2.6% to $65.3 million in 2023, then increased by 2.61% to $67.0 million in 2024, then fell by 16.42% to $56.0 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Research & Development are $56.0 million (Q4 2025), $57.2 million (Q3 2025), and $61.2 million (Q2 2025).